利奈唑胺补救治疗成人革兰阳性菌感染性心内膜炎的临床分析

A Clinical Analysis of Linezolid as Rescue Treatment for Adult Gram-Positive Bacterial Infective Endocarditis

摘要: 目的：通过临床病例回顾性研究，评价利奈唑胺补救治疗成人革兰阳性菌(G+)感染性心内膜炎(IE)的临床疗效及安全性。方法：收集南京医科大学附属南京医院感染科在2008年1月~2012年12月期间收治的确诊G+菌感染所致IE患者36例，其中利奈唑胺治疗组15例(以下简称为L组)，其他抗感染药物治疗组21例(以下简称对照组)；分析两组患者一般情况，比较两组患者治疗效果以及预后，数据处理通过SPSS软件。结果：两组患者均取得较好的疗效，L组与对照组的病死率分别为6.7%(1例)和9.5%(2例)，预后亦无显著性差异(P > 0.05)；L组仅1例患者出现血小板下降的不良反应，停药后即好转，其他患者均耐受良好。结论：利奈唑胺用于G+菌IE的治疗可获得良好疗效，而且耐受性好。对多重耐药G+菌引起的IE，尤其对传统疗法有禁忌或治疗失败，是一个极具优势的治疗选择。

Abstract: Objective: Retrospective study was carried out to evaluate the efficacy and safety of Linezolid as rescue treatment for adult gram-positive bacterial infective endocarditis. Methods: The study comprised 36 patients from department of infectious disease in Nanjing hospital affiliated to Nanjing Medical University, between 2008 and 2012. Fifteen patients enrolled in L group received Linezolid as rescue treatment for infective endocarditis which were unsuccessfully treated. Other twenty-one patients received conventional antibiotic therapy (Control group). We described baseline characteristics of the study population and compared L group with control group for the efficacy and the safety of treatment. The data were analyzed by SPSS software. Results: The thirty-three patients in two groups received effective treatment. No significant differences in the cure rate (80% vs. 81%) and in mortality (6.7% vs. 9.5%) were observed. Thrombocytopenia was present in only one patient of L group, and others were well tolerated. When we ended the Linezolid for treatment, the patients get well from thrombocytopenia. Conclusions: Linezolid was well tolerated and associated with the effective outcome as in patients with IE due to multiple resistant gram-positive, especially in patients who are fail to treated with conventional therapy or are poorly tolerated.

文章引用：王文静, 陶臻, 吴会玲, 申玉英. 利奈唑胺补救治疗成人革兰阳性菌感染性心内膜炎的临床分析[J]. 亚洲心脑血管病例研究, 2017, 5(1): 1-6. https://doi.org/10.12677/ACRVM.2017.51001

参考文献

[1]	Moellering, R.C. (2003) Linezolid: The First Oxazolidinone Antimicrobial. Annals of Internal Medicine, 138, 135-142. https://doi.org/10.7326/0003-4819-138-2-200301210-00015
[2]	Rubinstein, E., Isturiz, R., Standiford, H.C., et al. (2003) Worldwide Assessment of Linezolid’s Clinical Safety and Tolerability: Comparator Controlled Phase III Studies. Antimicrobial Agents and Chemotherapy, 47, 1824-1831. https://doi.org/10.1128/AAC.47.6.1824-1831.2003
[3]	Vinh, D.C. and Rubinstein, E. (2009) Linezolid: A Review of Safety and Tolerability. Journal of Infection, 59, S59- S74. https://doi.org/10.1016/S0163-4453(09)60009-8
[4]	Oramas-Shirey, M.P., Buchanan, L.V., Dileto-Fang, C.L., et al. (2001) Efficacy of Linezolid in a Staphylococcal Endocarditis Rabbit Model. Journal of Antimicrobial Chemotherapy, 47, 349-352. https://doi.org/10.1093/jac/47.3.349
[5]	Patel, R., Rouse, M.S., Piper, K.E. and Steckelberg, J.M. (2001) Linezolid Therapy of Vancomycin-Resistant Enterococcus Faeciumexperimental Endocarditis. Antimicrobial Agents and Chemotherapy, 45, 621-623. https://doi.org/10.1128/AAC.45.2.621-623.2001
[6]	Tsaganos, T., Skiadas, I., Koutoukas, P. et al. (2008) Efficacy and Pharmacodynamics of Linezolid, Alone and in Combination with Rifampicin, in an Experimental Model of Methicillin-Resistant Staphylococcus Aureus Endocarditis. Journal of Antimicrobial Chemotherapy, 62, 381-383. https://doi.org/10.1093/jac/dkn180
[7]	Mancino, P., Ucciferri, C., Falasca, K., Pizzigallo, E. and Vecchiet, J. (2008) Methicillin-Resistant Staphylococcus Epidermidis (MRSE) Endocarditis Treated with Linezolid. Scandinavian Journal of Infectious Diseases, 40, 67-73. https://doi.org/10.1080/00365540701509915
[8]	Muñoz, P., Rodríguez-Creixéms, M., Moreno, M., et al. (2007) Linezolid Therapy for Infective Endocarditis. Clinical Microbiology and Infection, 13, 211-215. https://doi.org/10.1111/j.1469-0691.2006.01585.x
[9]	Lauridsen, T.K., Arpi, M. and Bruun, N.E. (2010) Linezolid Therapy for Infectious Endocarditis. Ugeskrift for Læger, 172, 1215-1216.
[10]	Vardakas, K.Z., Kioumis, I. and Falagas, M.E. (2009) Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome. Current Drug Metabolism, 10, 2-12. https://doi.org/10.2174/138920009787048446
[11]	Gould, F.K. (2011) Linezolid: Safety and Efficacy in Special Populations. Journal of Antimicrobial Chemotherapy, 66, iv3-iv6. https://doi.org/10.1093/jac/dkr071
[12]	Bressler, A.M., Zimmer, S.M., Gilmore, J.L. and Somani, J. (2004) Peripheral Neuropathy Associated with Prolonged Use of Linezolid. The Lancet Infectious Diseases, 4, 528-531. https://doi.org/10.1016/S1473-3099(04)01109-0.